260
Participants
Start Date
August 17, 2006
Primary Completion Date
December 26, 2008
Study Completion Date
May 28, 2009
Prochymal®
2 infusions of 2 million cells/kg per week for 4 weeks
Placebo
2 infusions per week for 4 weeks
Standard of Care for GVHD
Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
Royal Melbourne Hospital, Parkville
Royal Brisbane Hospital, Herston
Kantonsspital Basel, Basel
Royal Perth Hospital, Perth
New York Presbyterian Hospital, New York
Mount Sinai Medical Center, New York
Columbia University/New York Presbyterian Hospital, New York
New York Medical College, Valhalla
Roswell Park, Buffalo
University of Rochester, Rochester
Western Pennsylvania Cancer Institute, Pittsburgh
Penn State Hershey Medical Center, Hershey
University of Maryland/Greenbaum, Baltimore
Virginia Commonwealth/Massey Cancer Center, Richmond
IRCCS Policlinico San Matteo, Pavia
Wake Forest Univeristy School of Medicine, Winston-Salem
Duke University, Durham
Medical University of South Carolina, Charleston
Emory University, Atlanta
Northside Hospital, Atlanta
University of Miami, Miami
All Children's Hospital, St. Petersburg
University of Alabama at Birmingham, Birmingham
Univeristy of Mississippi Medical Center, Jackson
University of Louisville, Louisville
Indiana Blood and Bone Marrow Transplant Center, Beech Grove
Karmanos/Wayne State University, Detroit
Univeristy of Iowa Hospitals and Clinics, Iowa City
Medical College of Wisconsin, Milwaukee
University of Wisconsin Madison, Madison
Mayo Clinic Rochester, Rochester
Northwestern Center for Clinical Research, Chicago
Rush University Medical Center, Chicago
University of Illinois - Chicago, Chicago
Universia degli Studi di Pesaro, Pesaro
University of Kansas Medical Center, Kansas City
University of Nebraska, Omaha
Louisiana State University, Shreveport
Texas Cancer Center at Medical City, Dallas
Baylor University, Dallas
Univeristy of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston
Texas Research Center, San Antonio
Arizona Cancer Center, Tucson
City of Hope, Duarte
Univeristy of California San Francisco, San Francisco
Oregon Health and Science University, Portland
Yale New Haven Hospital, New Haven
Tufts-New England Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Fred Hutchinson Cancer Research Center, Seattle
Co-Medica Research Network, Calgary
British Columbia's Children's Hospital, Vancouver
Cancer Care Manitoba, Winnipeg
Queen Elizabeth II Health Sciences Centre, Halifax
Hamilton Health Sciences Centre, Hamilton
London Health Sciences Centre- Westminster Campus, London
Ottawa Hospital, Ottawa
Toronto General Hospital, Toronto
Princess Margaret Hospital, Toronto
Maisonneuve-Rosemont Hospital, Montreal
Hopital Enfant-Jesus, Québec
Hopital du Saint-Sacrement, Québec
Barts & London School of Medicine, London
John Radcliffe Hospital, Headington
Bristol Royal Hospital for Children, Bristol
Glasgow Royal Infirmary, Glasgow
Leeds General Infirmary, Leeds
Lead Sponsor
Mesoblast, Inc.
INDUSTRY